Metanephric adenoma (MA) is a rare benign renal tumor comprised of a neoplastic proliferation of primitive metanephric tubular cells. A previous study identified BRAF V600E mutations in approximately 90% of MA and found that similar BRAF exon 15 mutations are exceedingly rare in other common renal tumors, including renal cell carcinoma and oncocytoma. A recent follow-up study has validated mutation-specific immunohistochemistry (IHC) for detection of BRAF V600E mutations in a small cohort of MA. Here, we extend these findings to a larger, independent cohort of MA, demonstrating an overall 88% sensitivity and 100% specificity for BRAF V600E IHC. In addition, we report 2 cases of MA with novel BRAF exon 15 mutations, including a V600D missense mutation and a compound V600D and K601L missense mutation. Finally, we evaluate BRAF V600E IHC in a large tissue microarray cohort of common renal tumors and find no significant expression in several renal cell carcinoma subtypes. These data support a role for BRAF V600E IHC in diagnostically challenging cases of MA and expand the spectrum of BRAF exon 15 mutations in this uncommon but unique renal neoplasm. BRAF exon 15 genomic sequencing of 4 MA cases. All 4 cases show the typical histomorphologic features of MA but demonstrate negative to weak cytoplasmic and/or nuclear staining. Adjacent non-neoplastic kidney parenchyma shows negative to weak cytoplasmic staining and weak to moderate nuclear staining. For 1 case, Sanger sequencing of BRAF exon 15 revealed no mutations (wild-type sequence at codons 600 and 601 shown in C). Two additional cases of V600E-negative MA showed novel BRAF exon 15 mutations by Sanger sequencing. For 1 case, compound substitution of adenine and thymidine at codon 600 for thymidine and guanine (arrowheads in F) results in the missense BRAF V600D mutation; for the other case, a complex compound substitution and/or indel at codons 600 and 601 (arrowheads in I) results in the compound missense BRAF mutations V600D and K601L. (These novel BRAF exon 15 mutations were subsequently confirmed by Sanger sequencing of the subcloned PCR product.) Finally, for 1 case, Sanger sequencing demonstrated a thymidine to adenine substitution at codon 600 (arrowhead in L), corresponding to a BRAF V600E missense mutation; this is the only instance of discordance between V600E mutation-specific IHC and Sanger sequencing.
M etanephric adenoma (MA) is a benign, often asymptomatic and incidentally identified renal tumor comprised of primitive metanephric tubular cells. [1] [2] [3] Patients commonly present in the fifth to sixth decade of life, and there is a slight female preponderance (F:M = approximately 2:1). Grossly, MA is usually a solid, solitary, unilateral mass that lacks a true fibrous capsule. On average, these tumors measure 5.5 cm in greatest dimension; however, they may be very small (< 0.5 cm) or large (>10 cm). Microscopically, MA usually appears solid at low magnification, although areas of cystic degeneration are sometimes present. [1] [2] [3] On higher magnification, these tumors consist of primitive metanephric tubular epithelial cells with scant cytoplasm and monotonous round to oval nuclei with fine chromatin and without nucleoli; these cells are usually arranged in small acinar structures, although areas with papillary, tubular, and glomeruloid growth patterns may be identified. Generally, there is minimal admixed paucicellular or hyalinized stroma, but cases may also demonstrate regressive changes, including dense sclerosis, dystrophic calcification, and/or psammomatous calcification. Mitotic activity is usually very low or absent in MA, and necrosis is very rare.
In the majority of cases, MA can be diagnosed on routine hematoxylin and eosin (H&E) stain; however, the differential diagnosis includes the solid variant of papillary renal cell carcinoma (RCC), as well as epithelialpredominant Wilms tumor (WT)-both of which require definitive treatment. [1] [2] [3] In challenging cases, particularly core needle biopsy specimens, immunohistochemistry (IHC) may be helpful. [3] [4] [5] MAs usually express WT1 and CD57 and can demonstrate focal CK7 expression in areas with elongated tubules. 3, 6 A recent study by Choueiri et al 7 has begun to shed light on the molecular underpinnings of this renal tumor, demonstrating that approximately 90% of MA harbor BRAF V600E mutations. BRAF encodes a serine/threonine-specific protein kinase upstream of the MAPK/ERK signaling pathway, and somatic activating BRAF mutations have been identified in a wide variety of common human malignancies, including melanoma, papillary thyroid carcinoma, and colonic adenocarcinoma. 8, 9 BRAF exon 15 mutations, including the V600E missense mutation, are frequently detected in a range of benign and malignant human tumors [10] [11] [12] [13] [14] [15] ; however, BRAF mutations in common non-MA renal tumors (ie, RCC, oncocytoma, WT) are either very infrequent (< 1%) or absent. 7, 16, 17 A mutation-specific antibody against the BRAF V600E protein product has been recently validated for IHC detection of BRAF V600E mutations in situ and utilized successfully in a variety of human tumor types. 10, [18] [19] [20] [21] [22] [23] [24] [25] [26] In a follow-up study to their work on BRAF V600E mutations in MA, Pinto et al 27 demonstrated that 6 of 6 (100%) MA cases, including 5 with confirmed BRAF V600E mutations, exhibited BRAF V600E expression by mutationspecific IHC. In contrast, <1% of cases from a large tissue microarray (TMA) cohort of common renal tumors demonstrated BRAF V600E expression.
In this study, we extend the findings reported by Pinto and colleagues to a larger, independent cohort of MA and report 2 cases of BRAF V600E-negative MA with novel BRAF exon 15 mutations. Finally, we evaluate BRAF V600E protein expression by mutation-specific IHC in a large TMA cohort of common renal tumors.
MATERIALS AND METHODS

Identification of MA Cases
This study was approved by the Institutional Review Board at the University of Michigan Medical School. A comprehensive retrospective search of the University of Michigan Health System (UMHS) pathology records database was performed to identify all available MA cases between 1985 and 2014, and a total of 11 such cases were available for the purposes of this study. H&E-stained slides from all cases were reviewed by 2 study pathologists (A.M.U. and R.M.), and representative formalin-fixed, paraffin-embedded (FFPE) tissue blocks were selected for BRAF V600E IHC and BRAF exon 15 sequencing.
Renal Tumor TMA Construction
A TMA representing common renal tumor types from 86 unique patients was constructed with FFPE tissue from partial or total nephrectomy specimens retrieved from the UMHS pathology specimen archive. This TMA included specimens from various renal tumor types, including: chromophobe RCC (n = 26); oncocytoma (n = 20); papillary RCC (n = 20); clear cell RCC (n = 16); RCC, unclassified (n = 2); clear cell papillary RCC (n = 1); and Xp11 translocation-associated RCC (n = 1). The tumor samples were represented on this TMA in at least triplicate cores, and samples of benign renal parenchyma from 10 patients served as internal controls.
BRAF V600E IHC
Whole sections were obtained from MA FFPE tissue blocks for BRAF V600E IHC (clone VE1; predilute; 790-4855; Ventana Medical Systems, Tucson, AZ), which was performed using a BenchMark ULTRA automated stainer and the ultraView Universal DAB Detection Kit (Ventana Medical Systems) by the CLIA-certified clinical IHC laboratory of the Department of Pathology at UMHS. This anti-BRAF V600E antibody is a mouse monoclonal antibody generated against a synthetic peptide representing the mutated BRAF V600E amino acid sequence (from amino acid 596 to 606; GLA-TEKSRWSG). 18, 20 Whole sections from a melanoma case with a confirmed BRAF V600E mutation were included as batch positive controls for BRAF V600E IHC; consistent with previously published data (as well as practical experience in the UMHS clinical IHC laboratory), the batch positive control demonstrated diffuse, moderate to strong cytoplasmic staining in melanoma cells but negative or weak staining in adjacent non-neoplastic tissue. 10, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] BRAF V600E IHC results for all MA cases were reviewed and scored independently by 2 study pathologists (A.M.U. and R.M.), who were blinded to both the general and specific BRAF exon 15 genomic sequencing results; only cases with diffuse, moderate to strong cytoplasmic staining in tumor cells were recorded as BRAF V600E IHC positive. For assessment of the renal tumor TMA, only cases with cores showing diffuse, moderate to strong cytoplasmic staining in tumor cells were recorded as BRAF V600E IHC positive.
BRAF Exon 15 Genomic Sequencing
For each MA case, tumor genomic DNA was isolated from FFPE tissue blocks using the QIAamp DNA FFPE Tissue Kit (Qiagen, Venlo, The Netherlands), according to the manufacturer's protocol. Commercially available male human genomic DNA (G1471; Promega, Madison, WI) served as a wild type BRAF exon 15 control, whereas genomic DNA isolated from SK-MEL-5 cells (HTB-70; ATCC, Manassas, VA) using the DNeasy Blood & Tissue Kit (Qiagen) served as a positive BRAF V600E control. BRAF exon 15 was amplified from 50 ng of genomic DNA by polymerase chain reaction (PCR) using flanking sequence-specific primers (forward: 5 0 -M13-TTTGTGAATA CTGGGAACTATGAAA-3 0 ; and reverse: 5 0 -TCATCCTA ACACATTTCAAGCC-3 0 ) and HotStarTaq DNA polymerase (Qiagen). The PCR conditions were as follows: initial denaturation at 951C for 15 minutes; 45 cycles of 941C for 60 seconds, 501C for 60 seconds, and 721C for 60 seconds; and final extension at 721C for 7 minutes. After confirming the expected amplicon size by standard agarose gel electrophoresis, all PCR products were incubated with ExoSAP-IT (Affymetrix, Santa Clara, CA) before bidirectional Sanger sequencing by the University of Michigan DNA Sequencing Core using the M13 forward and BRAF exon 15 PCR reverse primers. The resulting chromatograms were analyzed with Sequencher software, version 4.5 (Gene Codes, Ann Arbor, MI) and compared with reference sequence for BRAF exon 15 (NM_004333.4).
BRAF Exon 15 Subcloning
BRAF exon 15 PCR products from samples with complex somatic aberrations were resolved by standard gel electrophoresis, and the excised DNA fragments were purified using the S.N.A.P. Gel Purification Kit (Life Technologies, Waltham, MA). The purified PCR products were subcloned into the pCR4-TOPO vector using the TOPO TA Cloning Kit (Life Technologies) and transformed into Mach1 cells (Life Technologies) under kanamycin selection. Plasmid DNA was isolated from 10 independent bacterial colonies and subjected to Sanger sequencing with M13 forward or reverse primers by the University of Michigan Sequencing Core. The resulting chromatograms were analyzed as described above.
RESULTS
Clinicopathologic Features of a Retrospective MA Cohort
Eleven cases of MA from the UMHS pathology records database were available for this study ( Table 1 ). These patients included 6 women and 5 men, and the age at diagnosis ranged from 16 to 84 years (median = 45 y). Six of the tumors arose in the right kidney, whereas 4 developed in the left kidney; 1 MA occurred within the left side of a horseshoe kidney. One patient had polycythemia at the time of presentation, consistent with prior estimates of the incidence in patients with MA. 1 Eight of the cases were from partial or total nephrectomy specimens, whereas the other 3 were from core needle biopsies. The maximum tumor dimension ranged from 1.3 to 5.1 cm (median = 2.7 cm). These tumors demonstrated the typical histomorphologic spectrum of MA, including varying degrees of hyalinization, psammomatous calcification, and papillary, tubular, or glomeruloid growth patterns (see Table 1 for details).
BRAF V600E IHC in a Retrospective Cohort of MA
Given the reported high frequency of BRAF V600E mutations in MA, 7 as well as the high sensitivity and specificity of mutation-specific IHC for detecting these mutations in a wide variety of neoplasms (including MA), 10, 18, 19, 21, 22, [24] [25] [26] [27] we sought to examine BRAF V600E IHC in our retrospective MA cohort. Seven (64%) of the cases in our cohort demonstrated diffuse, moderate to strong cytoplasmic BRAF V600E IHC staining ( Fig. 1) , whereas the remaining 4 cases showed negative to weak cytoplasmic BRAF V600E IHC staining ( Fig. 2 ). Of note, in the vast majority of cases, the adjacent benign renal parenchyma showed variable weak cytoplasmic and weak to moderate nuclear staining. Overall, the tumor areas in the IHCpositive cases demonstrated unequivocal, diffuse moderate to strong cytoplasmic expression of mutated BRAF protein.
Concordance Between BRAF V600E Mutation Status by Mutation-specific IHC and Sanger Sequencing of BRAF Exon 15
As determined by mutation-specific IHC, the frequency of BRAF V600E mutations in our retrospective MA cohort was lower than previously reported (64% vs. 89%). 7 To further investigate this apparent difference, we interrogated our cohort for V600E mutations by Sanger sequencing of BRAF exon 15. Genomic DNA harvested from the SK-MEL-5 melanoma cell line (which carries the BRAF V600E mutation) and commercially available wildtype male human genomic DNA were utilized as positive and negative controls, respectively (data not shown). All 7 cases with diffuse, moderate to strong cytoplasmic BRAF V600E IHC staining harbored a thymidine to adenine substitution at codon 600 (ie, GTG-GAG), which corresponds to the BRAF V600E missense mutation (Fig. 1 ). In addition, for 1 of the remaining 4 cases with negative to weak cytoplasmic BRAF V600E IHC staining, Sanger sequencing demonstrated a BRAF V600E mutation (Figs. 2J-L). All other cases were negative for BRAF V600E mutations, and no other BRAF exon 15 mutations were detected in tumors harboring BRAF V600E mutations. Therefore, overall 8 (73%) of the cases in our retrospective MA cohort contain BRAF V600E mutations, and the overall sensitivity and specificity for mutationspecific IHC was 88% and 100%, respectively.
Novel BRAF Exon 15 Mutations in V600E-negative MA
For the 3 remaining cases with negative to weak cytoplasmic BRAF V600E IHC staining and without detectable BRAF V600E mutations by Sanger sequencing, (data not shown). No BRAF exon 15 mutations were identified in the third case ( Figs. 2A-C ).
BRAF V600E IHC in a Large TMA Cohort of Common Renal Tumors
Finally, previously published data suggest that BRAF V600E mutations are rare in other common renal tumors. 7, 17, 27 Investigation of the available provisional The Cancer Genome Atlas (TCGA; http://www.cbio portal.org) renal cancer data sets showed no BRAF codon 600 mutations in either chromophobe RCC (n = 66) or clear cell RCC (n = 523), and only 1 case of papillary RCC (n = 168) harbored a BRAF V600E mutation; no other BRAF exon 15 mutations were identified in this large RCC sequencing cohort. In addition, a recent study examined BRAF V600E IHC in a large TMA cohort of renal tumors, including clear cell RCC, papillary RCC, chromophobe RCC, and oncocytoma, and found that <1% of these tumors showed positive staining with this mutation-specific antibody. 27 We sought to independently extend these findings in a large TMA cohort of common renal tumors from our institution. BRAF V600E IHC was performed on a TMA comprising tumor samples from 86 unique patients (see the Materials and Methods section). Consistent with the rarity of documented BRAF V600E mutations in common renal tumors, none (0%) of the 84 tumors available for evaluation demonstrated diffuse, moderate to strong cytoplasmic staining (Fig. 3) . Importantly, representative cores of benign renal parenchyma from a subset of the TMA tumor cases demonstrated variable weak cytoplasmic and weak to moderate nuclear staining-similar to the aforementioned adjacent benign renal parenchyma in the MA cases. This reproducible (albeit nonspecific) background staining serves as a positive internal control for BRAF V600E IHC and, thereby, supports the experimental validity of negative BRAF V600E IHC in this TMA cohort of common renal tumors.
DISCUSSION
In this study, we examined BRAF V600E protein expression by mutation-specific IHC in a large cohort of MA. BRAF V600E IHC showed high sensitivity and specificity (88% and 100%, respectively) for the detection of BRAF V600E mutations (as assayed by Sanger sequencing) in this MA cohort. In addition, we report 3 cases of BRAF V600Enegative MA, including 2 with novel BRAF exon 15 mutations: 1 with a BRAF V600D mutation; and 1 with compound BRAF V600D and K601L mutations. Finally, we showed that BRAF V600E protein expression by mutation-specific IHC was essentially absent in a large TMA cohort of common renal tumors.
Our results are in concert with previously published data regarding BRAF V600E mutations and BRAF V600E protein expression in MA. 7, 27 One additional case of MA with a confirmed BRAF V600E mutation has been reported in the literature. 28 Thus, together with the cases reported in this study, 35 of 41 (85%) published genotyped MAs harbor BRAF V600E. When the novel BRAF mutations identified in our study are included, overall 37 of 41 (90%) published genotyped MAs contain BRAF exon 15 mutations. Similarly, of the published MA cases analyzed for BRAF V600E protein expression by mutation-specific IHC, 13 of 17 (76%) showed the diffuse, moderate to strong cytoplasmic staining characteristic of tumors with BRAF V600E mutations. 10, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The diagnosis of MA is often straightforward on routine H&E stains; however, some cases present challenging diagnostic dilemmas-particularly differentiating MA from the solid variant of papillary RCC. 4 In addition, abdominal radiographic imaging has increased the number of incidentally identified small renal masses, many of which are amenable to core needle biopsy diagnosis 29 ; however, the diagnosis of MA on core needle biopsy may be challenging because of limited material available for evaluation. In these cases, ancillary studies (especially IHC) may be helpful. [3] [4] [5] MAs characteristically express WT1 and CD57 and are frequently negative for CK7 and AMACR expression. 6 The value of BRAF V600E IHC in diagnostically challenging cases has not been specifically examined; however, given the relatively low frequency of documented BRAF V600E mutations and/or BRAF V600E expression in other common renal tumors, 7, 16, 17, 27 positive IHC staining for BRAF V600E supports the diagnosis of MA. At the same time, however, it is also important to recognize that the absence of BRAF V600E staining does not exclude the possibility of MA.
This study is the first to document non-V600E BRAF exon 15 mutations in MA. In the only other published large MA sequencing study, a small pilot cohort of 7 tumors was initially analyzed for oncogenic mutations by mass spectrometric genotyping with the OncoMap platform, which identified recurrent BRAF V600E mutations 7 ; an additional 22 cases were then analyzed for specific hotspot BRAF mutations (including BRAF V600D) by multiple base extension chemistry and secondarily validated by pyrosequencing with the BRAF Pyro kit (Qiagen) in a CLIA-certified laboratory. Interestingly, in contrast to our study, no non-V600E BRAF exon 15 mutations were identified. In addition to 1 case without detectable BRAF exon 15 mutations, we identified 2 cases with novel BRAF exon 15 mutations: 1 with a BRAF V600D mutation; and 1 with compound BRAF V600D and K601L mutations. Although the sample size of our cohort is too small to draw definitive conclusions, there was no obvious correlation between BRAF genotype and specific clinicopathologic factors (ie, age, histomorphologic features; Table 1 ).
BRAF V600D mutations are uncommon but have been identified in a variety of neoplasms, including melanoma, cholangiocarcinoma, and Langerhans cell histiocytosis. 9, [30] [31] [32] Similar to the more common V600E mutation, a variety of in vitro assays have demonstrated sensitivity of cultured cell lines harboring BRAF V600D mutations to the BRAF inhibitors vemurafenib and dabrafenib. [33] [34] [35] These findings suggest that BRAF V600D mutations may be functionally similar to V600E mutations in the tumorigenesis of MA-probably downstream activation of the MAPK/ERK signaling pathway.
The significance of the novel BRAF K601L mutation identified in our study is unclear. Although codon 601 is a hotspot for BRAF exon 15 mutations, according to the Catalogue of Somatic Mutations In Cancer (COSMIC) database, this particular mutation has only been reported in 1 other case-a lung adenocarcinoma. 36 Sanger sequencing of the subcloned PCR product showed that the compound mutation (V600D/K601L) in this case likely arose as a single frame-preserving indel event, and, given the concomitant V600D mutation, the K601L mutation may be of little additional functional significance. Overall, 4 of 41 (10%) published genotyped MAs do not harbor BRAF exon 15 mutations. Increasingly, recurrent somatic mutations in other signaling pathway genes have been described in BRAF V600E-negative neoplasms. 10, 37 In addition, a candidate tumor-suppressor gene in MA has been mapped to a small region on chromosome 2p, 38 and deletion of a portion of chromosome 2p has been documented in a BRAF V600E-positive MA case. 28 These findings suggest a need for additional comprehensive sequencing of MA-both cases with and without BRAF exon 15 mutations.
Finally, MA is thought to represent one end of a spectrum of benign metanephric neoplasms that includes metanephric adenofibroma (MAF) and metanephric stromal tumor (MST). Furthermore, this group of benign metanephric neoplasms has been hypothetically postulated as the possible hyperdifferentiated, benign counterpart to WT-a morphologically heterogenous group of tumors that may represent multiple distinct genetic entities. With this in mind, it is interesting to note the documented lack of BRAF mutations in WT. 16 Future studies should rigorously examine WT, MAF, and MST for BRAF exon 15 mutations. It will also be important to examine these tumors for BRAF V600E protein expression by mutation-specific IHC.
